AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06481709
Drug: RLF-OD032
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL oral suspension
Trial: NCT04766684
Drug: L.M.X.4 cream with J-Tip saline injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L.M.X.4 cream with J-Tip saline injection
Trial: NCT05330221
Drug: PHARM-PAL2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention.
Trial: NCT00339118
Drug: doxorubicin, cytoxan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04621110
Drug: intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
Trial: NCT06122714
Drug: Placebo Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Participants will be administered a single oral dose of matching placebo on Day 1.
Trial: NCT06122714
Drug: Placebo Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Participants will be administered a single dose of matching placebo on Day 1, and repeated dosing will commence from Day 4 until Day 11 (inclusive) and a single dose on Day 12.
Trial: NCT05919693
Drug: EYE103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EYE103 is a humanized antibody formulated for IVT administration
Trial: NCT05092191
Drug: Cannabis oil vs placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligibility, Screening and Baseline (T0):~Candidates will be seen by both research staff and a neurologist. Full written informed consent will be obtained before completing questionnaires and administering physical and medical evaluations. If eligibility is confirmed, a blood sample will be collected followed by participant randomisation .~Follow-up visits:~Randomized participants come back after 4 weeks (T1) for the same assessments administered at T0. Only participants who had a decrease in their level of spasticity can continue their participation in the same allocated arm for an additional period of 12 weeks.~At the end of the additional period of 12 weeks (T2), another visit is scheduled for a last assessments which are the same as T0 and T1.~Throughout study, courtesy calls will be scheduled and standard care for MS will also be offered to ensure participants 'safety and well-being.
Trial: NCT05823285
Drug: QLS31903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01μg/kg-2.16 μg/kg QLS31903 for injection
Trial: NCT06723366
Drug: Angong Niuhuang Pill (ANP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
Trial: NCT05064332
Drug: Ethinyl estradiol (EE) and levonogestrel (LN)
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Trial: NCT04296695
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV
Trial: NCT04296695
Drug: TDF/3TC/EFV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/3TC/EFV
Trial: NCT04584034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be delivered using a Babyhaler spacer device. The placebo will contain only the propellant HFA 134a.
Trial: NCT05129319
Drug: prabotulinumtoxinA
RxNorm normalized name: PrabotulinumtoxinA
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of glabellar rhytids
Trial: NCT06511336
Drug: Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: children will use Alkaline water as mouthwash daily for 3 weeks. each time they will use 10 ml of their mouthwash for 30 seconds
Trial: NCT06055361
Drug: BxC-I17e
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form : solution for injection
Trial: NCT06514144
Drug: BGF
RxNorm normalized name: ALCOHOL 620 mg in 1 g TOPICAL AEROSOL, FOAM [GBGF]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/glycopyrrolate/formoterol fumarate
Trial: NCT04763057
Drug: NeoPUTTY MTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing
Trial: NCT04763057
Drug: calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide the gold standard for IPT
Trial: NCT06055361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form : solution for injection
Trial: NCT05303779
Drug: Medication and eye glasses
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication and eye glasses used post strabismus surgery
Trial: NCT05695781
Drug: BRM421 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical drop of BRM421 ophthalmic solution.
Trial: NCT05695781
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical drop of vehicle (minus active) ophthalmic solution.
Trial: NCT06457828
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.
Trial: NCT05264025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT06732895
Drug: Navepegritide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks
Trial: NCT06732895
Drug: Placebo for navepegritide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide
Trial: NCT06162650
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
Trial: NCT04406948
Drug: MGCND00EP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take cannabis oil during the study
Trial: NCT04406948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will take carrier oil during the study
Trial: NCT05519579
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
Trial: NCT06579703
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized to a single dose of:~Arm A: 15 mg/mL (per mL) Arm B: 30 mg/mL (per mL)
Trial: NCT05244538
Drug: Propofol-remifentanil sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml.
Trial: NCT05934812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liquid nasal spray administered twice-daily
Trial: NCT01512901
Drug: Betamethasone Microsphere (DE-102） High Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05488626
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy per NCCN or other national guidelines.
Trial: NCT05488626
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant immunotherapy per national or institutional guidelines.
Trial: NCT04732455
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml normal saline over forty minutes pre each chemotherapy session until end of the cycle.
Trial: NCT04735549
Drug: Topical hormone estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
Trial: NCT04688242
Drug: administration of probiotics (Clostridium butyricum TO-A; Bacillus mesentericus TO-A; Streptococcus faecalisT-110) per anus
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital anal dilatation through anastomosis, with concomitant administration of probiotics per anus
Trial: NCT04766151
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
Trial: NCT05089617
Drug: YG1699
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699.
Trial: NCT05085587
Drug: Test
RxNorm normalized name: Testro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT05085587
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT00112879
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04151225
Drug: GSK2330811
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
Trial: NCT04151225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
Trial: NCT05056779
Drug: CD14152 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive loading dose of 60 mg (2×30 mg) SC injection of placebo at baseline. Thereafter 30 mg placebo will be administered via single SC injection Q4W up to week 12.
Trial: NCT05496374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching capsules will be administered orally.
Trial: NCT05496374
Drug: SPR720 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
Trial: NCT05004987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of placebo will mimic that of ESC.
Trial: NCT06717685
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)
Trial: NCT06733402
Drug: AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Trial: NCT06733402
Drug: AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Trial: NCT06733402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.
Trial: NCT01629420
Drug: KLH-2109
RxNorm normalized name: LINZAGOLIX CHOLINE 1 kg in 1 kg POWDER [KLH-2109 Choline]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04909242
Drug: DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive DZD9008 at different dose levels. There are 5 planned dose cohorts, starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008 or matching placebo, namely 100 mg, 200 mg, 300 mg and 400 mg.
Trial: NCT04909242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the double blind, randomised, placebo-controlled trial (Part A - SAD), healthy adult participants will be randomized to receive matching placebo for DZD9008 at different dose levels. There are 5 planned dose cohorts of matching placebo for DZD9008, starting from 50 mg once daily.
Trial: NCT04909242
Drug: DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part C, healthy adult participants will be enrolled to receive a single dose of DZD9008 as suspension in period 1 and as tablet in period 2.
Trial: NCT04909242
Drug: DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy adult participants will be randomized to receive DZD9008 single dose at a defined dose under a cross-over condition with or without food (low-fat in Part B; high-fat in Part D).
Trial: NCT04701151
Drug: Bacillus Calmette Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
Trial: NCT05097846
Drug: Group1 Vonoprazan Fumarate + amoxicillin + doxycycline
RxNorm normalized name: AMOXICILLIN/VONOPRAZAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan Fumarate + amoxicillin + doxycycline
Trial: NCT05097846
Drug: Group2 Vonoprazan Fumarate + furazolidone + doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan Fumarate + furazolidone + doxycycline
Trial: NCT05097846
Drug: Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
Trial: NCT05097846
Drug: Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Trial: NCT06138990
Drug: Clinical standard-of-care (physician's choice)
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical standard-of-care therapy for RR AML selected by the physician (physician's choice).
Trial: NCT05431569
Drug: 6MW3211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MW3211 injection ,30mg/kg,iv drip，Q2W
Trial: NCT05691257
Drug: Recombinant human eythropoietin and/or Iron agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)
Trial: NCT06412653
Drug: Zinc Acetate Dihydrate
RxNorm normalized name: Zinc Acetate Dihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
Trial: NCT06052241
Drug: shampoos and scalp serums
RxNorm normalized name: Selsun Blue Sensitive Scalp Shampoo Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: shampoos and scalp serums personalized according to their SPI-AI-defined scalp types
Trial: NCT06198465
Drug: adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adebrelimab: 1200mg，D1，q3w; Paclitaxel: 50mg/m2 D1/8/15； Lobaplatin: 50mg，iv 2h，d1; Fluorouracil: 400mg/m2，bolus iv，600mg/m2，iv 22h，d1-3；
Trial: NCT05547243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution
Trial: NCT04844580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aviptadil Placebo will be used for this arm.
Trial: NCT04482413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
Trial: NCT05855330
Drug: Arginine Hydrochloride
RxNorm normalized name: Arginine Hydrochloride
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
Trial: NCT06324266
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.
Trial: NCT06377072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
Trial: NCT05749848
Drug: [¹⁴C]-LY3372689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06139536
Drug: BAT4706 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
Trial: NCT06139536
Drug: BAT1308 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
Trial: NCT02911961
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
Trial: NCT05181852
Drug: IP2015, dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT05181852
Drug: IP2015, dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT05181852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05966246
Drug: Arm I : Experimental (Prucalopride succinate group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
Trial: NCT05966246
Drug: Arm II : Control (Mosapride citrate group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control gourp taking mosapride citrate from day 1 day 5 after surgery
Trial: NCT04572867
Drug: IV Diuretics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
Trial: NCT05564442
Drug: 20% benzocaine gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
Trial: NCT05118334
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (IBI310 1mg/kg IV, Q3W+ Sintilimab 200 mg IV, Q3W) until progressive disease,intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Trial: NCT06218199
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03244072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracameral injection